Guanfacine
Product Images NDC 63629-1103

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 63629-1103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Image 05)

A pharmacokinetic curve comparing guanfacine plasma concentration (mg/mL) over 24 hours between two formulations: guanfacine extended-release tablets 1 mg once daily (solid squares) and Tenex 1 mg once daily (solid triangles). The y-axis shows plasma concentration, and the x-axis shows time in hours.*

FDA Label Image

Figure 2 (Image 06)

A pharmacokinetic chart depicting fold changes and 90% confidence intervals for Cmax and AUC values influenced by various compounds affecting CYP3A4/5 enzymes. The chart includes human and computer simulation data for ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate. It plots changes relative to a reference on a horizontal axis from 0 to 5.*

FDA Label Image

Figure 3 (Image 07)

A horizontal forest plot showing fold change with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of interacting drugs oral methylphenidate and lisdexamfetamine dimesylate, relative to a reference. The chart illustrates no significant change around the fold change value of 1.0.*

FDA Label Image

Label (Lbl636291103)

Label for Guanfacine Extended-Release Tablets, USP 2 mg by Bryant Ranch Prepack. The label shows NDC 63629-1103-1, package count of 100 tablets, and indicates the product is Rx only. Manufactured by Ohm Laboratories, Inc., New Brunswick, NJ, and relabeled by Bryant Ranch Prepack, Burbank, CA. Storage and handling instructions are included.*

FDA Label Image

Spl-guanfacine-figure 4 (Spl Guanfacine Figure 4)

A Kaplan-Meier survival curve showing treatment failure percentage over time in days. The chart compares two groups labeled Placebo and SPD503, with Placebo shown as a solid line and SPD503 as a dashed line, plotting treatment failure rates increasing over approximately 200 days.*

FDA Label Image

Structure (Structure)

Chemical structure of guanfacine hydrochloride showing a dichlorinated benzene ring attached to an acetamide group linked to a guanidine moiety, with the hydrochloride salt component indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.